{
    "data": [
        {
            "id": "4660040",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-28T01:30:44-05:00",
                "isLockedPro": false,
                "commentCount": 48,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1481187163/image_1481187163.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovations",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "107268",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "511648",
                            "type": "sentiment"
                        },
                        {
                            "id": "511649",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4660040-pfizer-advantage-high-dividend-jn1-variant-therapeutic-innovations"
            }
        },
        {
            "id": "4659631",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-26T09:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 144,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810122/image_1445810122.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104513",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "511569",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4659631-pfizer-why-i-am-buying-this-stock-after-dividend-increase"
            }
        },
        {
            "id": "4658955",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-21T01:08:28-05:00",
                "isLockedPro": false,
                "commentCount": 183,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1481187163/image_1481187163.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Buy The Panic",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105995",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "510532",
                            "type": "sentiment"
                        },
                        {
                            "id": "510533",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4658955-pfizer-buy-the-panic"
            }
        },
        {
            "id": "4658881",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-20T13:46:26-05:00",
                "isLockedPro": false,
                "commentCount": 160,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1465073112/image_1465073112.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Is Not Cheap, And The 5.7% Yield Is Not As Safe As You Might Think",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "107131",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "510538",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4658881-pfizer-is-not-cheap-and-the-5-7-percent-yield-is-not-as-safe-as-you-might-think"
            }
        },
        {
            "id": "4658691",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-19T12:56:59-05:00",
                "isLockedPro": false,
                "commentCount": 68,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503314/image_521503314.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly Looks Overvalued, Buy Pfizer Instead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "510213",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4658691-eli-lilly-looks-overvalued-buy-pfizer-instead"
            }
        },
        {
            "id": "4658427",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-18T07:46:37-05:00",
                "isLockedPro": false,
                "commentCount": 71,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/84459655/image_84459655.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Not A Bad Time To Start A Position And Add On Further Weakness",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106896",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "509896",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4658427-pfizer-stock-not-bad-time-to-start-position-add-weakness"
            }
        },
        {
            "id": "4658260",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-17T13:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 119,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1283384596/image_1283384596.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Lost All Of Its Covid Glory, But Don't Give Up Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "509675",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4658260-pfizer-lost-all-of-its-covid-glory-but-dont-give-up-now"
            }
        },
        {
            "id": "4658187",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-16T14:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 124,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1424843181/image_1424843181.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: The Bears Have Won This Round",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106485",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "509231",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4658187-pfizer-bears-have-won-this-round"
            }
        },
        {
            "id": "4658073",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-15T09:45:32-05:00",
                "isLockedPro": false,
                "commentCount": 64,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Dividend Boost At The Right Time",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25319",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "509502",
                            "type": "sentiment"
                        },
                        {
                            "id": "509509",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4658073-pfizer-dividend-boost-at-the-right-time"
            }
        },
        {
            "id": "4657723",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-13T13:06:50-05:00",
                "isLockedPro": false,
                "commentCount": 238,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1360516768/image_1360516768.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer 2024 Guidance - Relentless COVID Pain Isn't Over",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "509054",
                            "type": "sentiment"
                        },
                        {
                            "id": "509062",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4657723-pfizer-2024-guidance-relentless-covid-pain-not-over"
            }
        },
        {
            "id": "4655948",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-05T00:55:04-05:00",
                "isLockedPro": false,
                "commentCount": 48,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1497108072/image_1497108072.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Vs. Pfizer: Better Pharma Stock?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104695",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "506434",
                            "type": "sentiment"
                        },
                        {
                            "id": "506435",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4655948-johnson-and-johnson-vs-pfizer-better-pharma-stock"
            }
        },
        {
            "id": "4655895",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-04T18:04:34-05:00",
                "isLockedPro": false,
                "commentCount": 166,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1293330778/image_1293330778.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: This Year's Disaster Should Set The Stage For A Strong 2024",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56142",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "506501",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4655895-pfizer-this-years-disaster-should-set-the-stage-for-a-strong-2024"
            }
        },
        {
            "id": "4655688",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-04T09:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1200508619/image_1200508619.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Slimming Down After COVID Franchise And Obesity Pipeline Setbacks",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40031",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "506482",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4655688-pfizer-stock-slimming-down-after-covid-franchise-obesity-pipeline-setbacks-reaffirm-buy"
            }
        },
        {
            "id": "4655611",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-03T02:31:09-05:00",
                "isLockedPro": false,
                "commentCount": 142,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/121279006/image_121279006.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Between Hope, Despair, And A 5.7% Yield",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "92986",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "506283",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4655611-pfizer-between-hope-despair-and-a-5-7-percent-yield"
            }
        },
        {
            "id": "4655457",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-01T13:56:32-05:00",
                "isLockedPro": false,
                "commentCount": 104,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1415584692/image_1415584692.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Disastrous 2023 Hits New Low With Weight Loss Drug Failure",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "506179",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4655457-pfizer-disastrous-2023-hits-new-low-with-weight-loss-drug-failure"
            }
        },
        {
            "id": "4653133",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-21T07:10:00-05:00",
                "isLockedPro": false,
                "commentCount": 320,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1288877316/image_1288877316.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "503408",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4653133-pfizer-fantastic-buy-so-are-these-9-percent-yielding-blue-chips"
            }
        },
        {
            "id": "4652725",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-17T13:16:55-05:00",
                "isLockedPro": false,
                "commentCount": 49,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418907713/image_1418907713.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Stock: Cheap But Will Remain Cheap, For Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104783",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "502802",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4652725-pfizer-stock-cheap-but-will-remain-cheap-for-now"
            }
        },
        {
            "id": "4651641",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-14T13:20:56-05:00",
                "isLockedPro": false,
                "commentCount": 199,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1482617492/image_1482617492.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Victim Of Vaccine Side Effects",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56062",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "501890",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4651641-pfizer-victim-of-vaccine-side-effects"
            }
        },
        {
            "id": "4650990",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-12T05:47:32-05:00",
                "isLockedPro": false,
                "commentCount": 139,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/84459655/image_84459655.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "High-Quality Dividend Growth Near 52-Week Lows: Pfizer Is Phenomenal",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106014",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "501330",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4650990-high-quality-dividend-growth-near-52-week-lows-pfizer-is-phenomenal"
            }
        },
        {
            "id": "4646398",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-02T09:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 63,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/121279005/image_121279005.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Value Investment Opportunity After Recent Price Decline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106842",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "498542",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4646398-pfizer-value-investment-opportunity-after-recent-price-decline"
            }
        },
        {
            "id": "4643238",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-25T07:55:40-04:00",
                "isLockedPro": false,
                "commentCount": 76,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1301962683/image_1301962683.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Ignore The Noise And Buy This Deep Value",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106913",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "496417",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4643238-pfizer-ignore-noise-buy-deep-value"
            }
        },
        {
            "id": "4643009",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-24T15:15:34-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1229554948/image_1229554948.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Seagen's Acquisition: EU Approval And Potential Upside",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "496096",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4643009-seagen-acquisition-eu-approval-and-potential-upside"
            }
        },
        {
            "id": "4642853",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-24T09:05:12-04:00",
                "isLockedPro": false,
                "commentCount": 54,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418907713/image_1418907713.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Huge Upside Potential And 5%+ Yield",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105218",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "495834",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4642853-pfizer-huge-upside-potential-and-5-percent-plus-yield"
            }
        },
        {
            "id": "4642657",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-23T13:19:04-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418907713/image_1418907713.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Stock: Interesting, If Discipline Returns",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "495612",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4642657-pfizer-stock-interesting-if-discipline-returns"
            }
        },
        {
            "id": "4641439",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-18T02:08:48-04:00",
                "isLockedPro": false,
                "commentCount": 63,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1481187163/image_1481187163.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's 4.9% Yield: A Contrarian Buy Near 1-Year Lows",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106128",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "494142",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4641439-pfizers-4-9-percent-yield-a-contrarian-buy-near-1-year-lows"
            }
        },
        {
            "id": "4641233",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-17T09:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 57,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418907713/image_1418907713.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Washed-Out And On The Verge Of A Huge Turnaround",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "494125",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4641233-pfizer-washed-out-and-on-the-verge-of-a-huge-turnaround"
            }
        },
        {
            "id": "4640939",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-16T02:53:47-04:00",
                "isLockedPro": false,
                "commentCount": 32,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072775768/image_1072775768.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Sequel: Return Of The Value Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103833",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "493639",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4640939-pfizers-sequel-return-of-value-stock"
            }
        },
        {
            "id": "4640899",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-15T20:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 386,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1407371720/image_1407371720.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Brutal End To COVID Gravy Train",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "493628",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4640899-pfizer-brutal-end-covid-gravy-train"
            }
        },
        {
            "id": "4640851",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-15T04:23:19-04:00",
                "isLockedPro": false,
                "commentCount": 131,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1356405163/image_1356405163.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Buy This Big Pharma Stock For Safe Income And Deep Value",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104980",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "493103",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4640851-pfizer-buy-this-big-pharma-stock-for-safe-income-and-deep-value"
            }
        },
        {
            "id": "4637892",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-28T08:59:14-04:00",
                "isLockedPro": false,
                "commentCount": 88,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/121279005/image_121279005.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Sell-Off Overdone, Healthy Pipeline To Sustain Above 15% ROE",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106789",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "489384",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4637892-pfizer-stock-selloff-overdone-healthy-pipeline-sustain-strong-roe"
            }
        },
        {
            "id": "4637110",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-25T07:44:15-04:00",
                "isLockedPro": false,
                "commentCount": 105,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418907713/image_1418907713.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Protracted Selloff Makes This Best Time To Buy For A Decade",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "488010",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4637110-pfizer-protracted-selloff-makes-this-best-time-to-buy-for-a-decade"
            }
        },
        {
            "id": "4634064",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-09T03:17:14-04:00",
                "isLockedPro": false,
                "commentCount": 195,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1446969434/image_1446969434.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Vs. Gilead Sciences: COVID-19 Battle Of Pharma Titans",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "484363",
                            "type": "sentiment"
                        },
                        {
                            "id": "484364",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4634064-pfizer-vs-gilead-sciences-covid-19-battle-of-pharma-titans"
            }
        },
        {
            "id": "4633646",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-07T07:09:50-04:00",
                "isLockedPro": false,
                "commentCount": 61,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418907713/image_1418907713.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Still Attractive Despite Recent Acquisitions",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105586",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "483752",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4633646-pfizer-still-attractive-despite-recent-acquisitions"
            }
        },
        {
            "id": "4632170",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-02T12:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 78,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/959257636/image_959257636.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: The Floor To This Decline Remains To Be Seen",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106485",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "481896",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4632170-pfizer-the-floor-to-this-decline-remains-to-be-seen"
            }
        },
        {
            "id": "4632104",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-30T16:04:07-04:00",
                "isLockedPro": false,
                "commentCount": 46,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1164897005/image_1164897005.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer, Moderna And COVID Vaccine Patents: Implications Of Legal Cases",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "482269",
                            "type": "sentiment"
                        },
                        {
                            "id": "482270",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4632104-pfizer-moderna-and-covid-vaccine-patents-implications-of-legal-cases"
            }
        },
        {
            "id": "4630783",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-24T08:03:08-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418907713/image_1418907713.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Searching For A Bottom",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40031",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "480659",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4630783-pfizer-searching-for-bottom"
            }
        },
        {
            "id": "4629272",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-17T11:55:41-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Stock: The Right Time To Buy Now (Technical Analysis)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106871",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "479032",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4629272-pfizer-stock-the-right-time-to-buy-now-technical-analysis"
            }
        },
        {
            "id": "4628061",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-14T08:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 54,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418907713/image_1418907713.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Doubling Down Buying Opportunity Is Here",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "477856",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4628061-pfizer-doubling-down-buying-opportunity-here"
            }
        },
        {
            "id": "4627532",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-11T15:14:02-04:00",
                "isLockedPro": false,
                "commentCount": 289,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/173608164/image_173608164.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Unexpected Strength: Bullish Case Emerges Amid New Covid-19 Wave",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "477511",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4627532-pfizers-unexpected-strength-bullish-case-emerges-amid-new-covid-19-wave"
            }
        },
        {
            "id": "4619362",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-25T00:18:11-04:00",
                "isLockedPro": false,
                "commentCount": 125,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1410672330/image_1410672330.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "How Pfizer Stands In My Investment Plans For Our Dividend Growth Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22501",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "472894",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4619362-pfizer-stock-investment-plans-dividend-growth-portfolio"
            }
        },
        {
            "id": "4619229",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-24T16:00:47-04:00",
                "isLockedPro": false,
                "commentCount": 208,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418907713/image_1418907713.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Significant Plunge, Offering Exceptional Buying Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "472853",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4619229-pfizer-significant-plunge-offering-exceptional-buying-opportunity"
            }
        },
        {
            "id": "4617416",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-17T11:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 39,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/171340691/image_171340691.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: A 4.5% Dividend Yield Is A Gift",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106913",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "470815",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4617416-pfizer-a-4-5-percent-dividend-yield-is-a-gift"
            }
        },
        {
            "id": "4616032",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-10T05:28:13-04:00",
                "isLockedPro": false,
                "commentCount": 68,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1227739922/image_1227739922.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: A Worthwhile Dividend Play At A Cheap Valuation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106231",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "469164",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4616032-pfizer-stock-worthwhile-dividend-play-at-cheap-valuation"
            }
        },
        {
            "id": "4614605",
            "type": "article",
            "attributes": {
                "publishOn": "2023-06-30T09:15:22-04:00",
                "isLockedPro": false,
                "commentCount": 103,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1398709804/image_1398709804.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Great Market Miscalculation: Pfizer's True Value Remains Untapped",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "467423",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4614605-great-market-miscalculation-pfizer-true-value-remains-untapped"
            }
        },
        {
            "id": "4614199",
            "type": "article",
            "attributes": {
                "publishOn": "2023-06-28T15:51:29-04:00",
                "isLockedPro": false,
                "commentCount": 147,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1495273475/image_1495273475.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Come For The Dividend - Stay For The Dividend",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "466999",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4614199-pfizer-stock-come-and-stay-for-dividend"
            }
        },
        {
            "id": "4611292",
            "type": "article",
            "attributes": {
                "publishOn": "2023-06-13T16:55:45-04:00",
                "isLockedPro": false,
                "commentCount": 49,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Deeper Value Found Amidst Diversified Pipelines",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106899",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "462951",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4611292-pfizer-deeper-value-found-amidst-diversified-pipelines"
            }
        },
        {
            "id": "4610435",
            "type": "article",
            "attributes": {
                "publishOn": "2023-06-08T21:45:26-04:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/485712204/image_485712204.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Or Gilead Sciences? Let's Ask Peter Lynch",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "462180",
                            "type": "sentiment"
                        },
                        {
                            "id": "462181",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4610435-pfizer-or-gilead-sciences-stock-lets-ask-peter-lynch"
            }
        },
        {
            "id": "4608060",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-30T00:11:19-04:00",
                "isLockedPro": false,
                "commentCount": 45,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/121279005/image_121279005.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: The New Oral Weight Loss Therapy Could Be A Game Changer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106586",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "459346",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4608060-pfizer-stock-new-oral-weight-loss-therapy-meaningful-upside-potential"
            }
        },
        {
            "id": "4607915",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-29T09:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 32,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1486856987/image_1486856987.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Not Quite Dead Money Walking",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106485",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "457700",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4607915-pfizer-stock-cautiously-rating-buy"
            }
        },
        {
            "id": "4607772",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-27T00:39:09-04:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1390069781/image_1390069781.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Undervaluation In The Post-COVID-19 Era",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "459180",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4607772-pfizer-pfe-undervaluation-in-the-post-covid-19-era"
            }
        },
        {
            "id": "4606440",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-22T09:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 41,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Yielding 4.5% Is Getting Added To My Dividend Harvesting Portfolio And Maybe The Main Account",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104513",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "457568",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4606440-pfizer-yielding-4-5-percent-is-getting-added-to-my-dividend-harvesting-portfolio-and-maybe-the-main-account"
            }
        },
        {
            "id": "4605853",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-18T15:17:20-04:00",
                "isLockedPro": false,
                "commentCount": 130,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1372778958/image_1372778958.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Ridiculous Selloff To A 2-Year Low",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "457068",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4605853-pfizer-ridiculous-selloff-to-a-two-year-low"
            }
        },
        {
            "id": "4605670",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-18T08:48:28-04:00",
                "isLockedPro": false,
                "commentCount": 36,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Getting Enticing",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25319",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "456924",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4605670-pfizer-getting-enticing"
            }
        },
        {
            "id": "4605576",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-17T23:59:43-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1372778958/image_1372778958.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: A Lackluster Valuation And Soft Growth Outlook Despite Strong Free Cash Flow",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106553",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "456902",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4605576-pfizer-stock-lackluster-valuation-soft-growth-outlook-strong-free-cash-flow"
            }
        },
        {
            "id": "4598995",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-02T15:27:42-04:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Q1 Earnings: COVID Franchise Outperforms While Investors Play Long Game",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "453649",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4598995-pfizer-q1-earnings-covid-franchise-outperforms-investors-play-long-game"
            }
        },
        {
            "id": "4594521",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-17T13:43:35-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1456194325/image_1456194325.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Vs. AstraZeneca: Which Is Better For Long-Term Investors?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "450381",
                            "type": "sentiment"
                        },
                        {
                            "id": "450382",
                            "type": "sentiment"
                        },
                        {
                            "id": "450383",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4594521-pfizer-vs-astrazeneca-which-is-better-for-long-term-investors"
            }
        },
        {
            "id": "4593029",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-09T06:33:31-04:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1372778958/image_1372778958.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Trying To Acquire Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "448668",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4593029-pfizer-trying-to-acquire-growth"
            }
        },
        {
            "id": "4591656",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-01T00:55:30-04:00",
                "isLockedPro": false,
                "commentCount": 165,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1411980068/image_1411980068.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Don't Bank On mRNA Vaccines",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105052",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "447277",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4591656-pfizer-dont-bank-on-mrna-vaccines"
            }
        },
        {
            "id": "4587120",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-13T22:18:42-04:00",
                "isLockedPro": false,
                "commentCount": 34,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1389510306/image_1389510306.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What Pfizer Is Getting From The Seagen Acquisition",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40031",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "443610",
                            "type": "sentiment"
                        },
                        {
                            "id": "443611",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4587120-pfizer-stock-what-it-gets-from-seagen-acquisition"
            }
        },
        {
            "id": "4587037",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-13T13:18:29-04:00",
                "isLockedPro": false,
                "commentCount": 47,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1084006256/image_1084006256.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Buys Seagen - Why This Deal May Not Please Shareholders",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "443637",
                            "type": "sentiment"
                        },
                        {
                            "id": "443638",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4587037-pfizer-buys-seagen-deal-may-not-please-shareholders"
            }
        },
        {
            "id": "4584771",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-06T03:11:42-05:00",
                "isLockedPro": false,
                "commentCount": 33,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1226994328/image_1226994328.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What To Expect From Pfizer In The Post-COVID-19 Era",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "441972",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4584771-pfizer-stock-what-to-expect-in-post-covid-19-era"
            }
        },
        {
            "id": "4584673",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-05T07:30:00-05:00",
                "isLockedPro": false,
                "commentCount": 94,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Crucial Moment For Buyers At Its 52-Week Low",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "441794",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4584673-pfizer-crucial-moment-for-buyers-52-week-low"
            }
        },
        {
            "id": "4582504",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-27T14:43:46-05:00",
                "isLockedPro": false,
                "commentCount": 98,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1427861318/image_1427861318.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Needs The Seagen Deal",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "440716",
                            "type": "sentiment"
                        },
                        {
                            "id": "440717",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4582504-pfizer-needs-seagen-deal"
            }
        },
        {
            "id": "4582396",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-27T10:58:25-05:00",
                "isLockedPro": false,
                "commentCount": 52,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer-Seagen: Dividend Risk Evaluation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25319",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "440634",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4582396-pfizer-seagen-dividend-risk-evaluation"
            }
        },
        {
            "id": "4576358",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-08T11:26:44-05:00",
                "isLockedPro": false,
                "commentCount": 96,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Time To Be Fearless",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "436519",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4576358-pfizer-time-to-be-fearless"
            }
        },
        {
            "id": "4575261",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-04T10:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Spotlight On Google, Disney, Regeneron Pharmaceuticals And Hesai Group IPO",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4575261-stocks-to-watch-spotlight-on-google-disney-regeneron-pharmaceuticals-and-hesai-group-ipo"
            }
        },
        {
            "id": "4574822",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-03T16:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 82,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1358642489/image_1358642489.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: The Covid Reset Makes Sense",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106485",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "432163",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4574822-pfizer-the-covid-reset-makes-sense"
            }
        },
        {
            "id": "4573058",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-27T14:01:58-05:00",
                "isLockedPro": false,
                "commentCount": 208,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1198972656/image_1198972656.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Cash King In Big Pharma: Pfizer (Rating Upgrade)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56142",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "433960",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4573058-the-cash-king-in-big-pharma-pfizer-rating-upgrade"
            }
        },
        {
            "id": "4571305",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-20T16:47:28-05:00",
                "isLockedPro": false,
                "commentCount": 61,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1077106476/image_1077106476.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer And L3Harris: 2 Recession-Resistant Companies Worth Considering",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "432656",
                            "type": "sentiment"
                        },
                        {
                            "id": "432657",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4571305-pfizer-and-l3harris-two-recession-resistant-companies-worth-considering"
            }
        },
        {
            "id": "4569712",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-13T07:30:00-05:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1344323398/image_1344323398.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Recent COVID-Related Headlines Call For An Updated Assessment",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104805",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "431188",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4569712-pfizer-recent-covid-related-headlines-updated-assessment"
            }
        },
        {
            "id": "4569511",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-12T10:53:34-05:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Don't Expect Another Record Year",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "430976",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4569511-pfizer-dont-expect-another-record-year"
            }
        },
        {
            "id": "4569460",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-12T05:37:07-05:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Shares Have Priced In The Expected Earnings Declines",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20102",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "430932",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4569460-pfizer-shares-priced-expected-earnings-declines"
            }
        }
    ]
}